Filter

Refine by date

—
  • Print
  • Save
  • Print

Diagnosis and Treatment > Medication > Capecitabine

You are looking at 1 - 1 of 1 items

Marina Tsoli Department of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Marina Tsoli in
Google Scholar
PubMed Close
,
Anna Angelousi Department of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Anna Angelousi in
Google Scholar
PubMed Close
,
Dimitra Rontogianni Department of Histopathology, Evagelismos General Hospital, Athens, Greece

Search for other papers by Dimitra Rontogianni in
Google Scholar
PubMed Close
,
Constantine Stratakis Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA

Search for other papers by Constantine Stratakis in
Google Scholar
PubMed Close
, and
Gregory Kaltsas Department of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed Close

Summary

Parathyroid carcinoma is an extremely rare endocrine malignancy that accounts for less than 1% of cases of primary hyperparathyroidism. We report a 44-year-old woman who presented with fatigue and diffuse bone pain. Laboratory findings revealed highly elevated serum calcium and parathyroid hormone (PTH) levels and a 4.5 × 3 × 2.5 cm cystic lesion in the lower pole of the right thyroid lobe that was shown histologically to be a parathyroid carcinoma. Ten years later, the patient developed brain and pulmonary metastases and recurrence of PTH-related hypercalcemia. Treatment of hypercalcemia along with localized radiotherapy and various chemotherapy regimens failed to induce a biochemical or radiological response. In conclusion, parathyroid carcinoma is a rare neoplasia that may develop metastases even after prolonged follow-up, for which there is no evidence-based treatment besides surgery. Different chemotherapeutic schemes did not prove to be of any benefit in our case highlighting the need for registering such patients to better understand tumor biology and develop specific treatment.

Learning points:

  • Metastases can develop many years after parathyroid cancer diagnosis.

  • Surgery is the only curative treatment for parathyroid carcinoma.

  • Chemotherapy and radiotherapy prove to be ineffective in parathyroid cancer treatment.

  • Patient registering is required in order to delineate underlining pathology and offer specific treatment.

Taxonomy:
Clinical Overview, Gland/Organ, Parathyroid, Topic, Endocrine-related cancer, Condition/ Syndrome, Metastatic carcinoma, Parathyroid carcinoma, Patient Demographics, Age, Adult, Gender, Female, Ethnicity, White, Country of Treatment, Greece, Diagnosis and Treatment, Signs and Symptoms, Bone pain, Fatigue, Hypercalcaemia, Hypophosphataemia, Myasthaenia, Polydipsia, Polyuria, Investigation, Alkaline phosphatase, Calcium (serum), CT scan, Histopathology, MRI, Phosphate (serum), PTH, Radionuclide imaging, Sestamibi scan, Ultrasound scan, Intervention, Fluid repletion, Lymphadenectomy, Parathyroidectomy, Radiotherapy, Thyroidectomy, Medication, Bisphosphonates, Calcium carbonate, Capecitabine, Cinacalcet, Fluorouracil, Furosemide, Pamidronate, Temozolomide, Zoledronic acid, Related Disciplines, Oncology, Publication Details, Case Report Type, Unique/unexpected symptoms or presentations of a disease
DOI:
https://doi.org/10.1530/EDM-17-0106
Volume/Issue:
Volume 2017: Issue 1
Open access